Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core

The use of p53-MDM2 inhibitors is a prospective strategy in anti-cancer therapy for tumors expressing wild type p53 protein. In this study, we have applied a simple approach of two-step synthesis of imidazoline-based alkoxyaryl compounds, which are able to efficiently inhibit p53-MDM2 protein–protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazanov, Daniil R., Pervushin, Nikolay V., Savin, Egor V., Tsymliakov, Michael D., Maksutova, Anita I., Savitskaya, Victoria Yu., Sosonyuk, Sergey E., Gracheva, Yulia A., Seliverstov, Michael Yu., Lozinskaya, Natalia A., Kopeina, Gelina S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027661/
https://www.ncbi.nlm.nih.gov/pubmed/35455441
http://dx.doi.org/10.3390/ph15040444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027661/
https://www.ncbi.nlm.nih.gov/pubmed/35455441
http://dx.doi.org/10.3390/ph15040444

Ejemplares similares